临床病理特点 | 低IEF组 | 高IEF组 | P value |
| N = 32 (%) | N = 41 (%) | |
性别 |
|
| 0.001 |
男 | 4 (12.5) | 21 (51.22) |
|
女 | 28 (87.5) | 20 (48.78) |
|
年龄(岁) |
|
| 0.166 |
<65 | 23 (71.875) | 23 (56.10) |
|
³65 | 9 (28.125) | 18 (43.90) |
|
肿瘤分期 |
|
| 0.01 |
III期 | 19 (59.375) | 12 (29.27) |
|
IV期 | 13 (40.625) | 29 (70.73) |
|
靶向药物 |
|
| 0.012 |
厄洛替尼 | 6 (18.75) | 8 (19.51) |
|
吉非替尼 | 18 (56.25) | 10 (24.39) |
|
埃克替尼 | 8 (25) | 23 (56.10) |
|
中性粒细胞计数(109/L) |
|
| 0.588 |
<6.3 | 30 (93.75) | 37 (90.24) |
|
≥6.3 | 2 (6.25) | 4 (9.76) |
|
单核细胞计数(109/L) |
|
| 0.295 |
<0.6 | 28 (87.5) | 32 (78.05) |
|
≥0.6 | 4 (12.5) | 9 (21.95) |
|
纤维蛋白原(g/L) |
|
| 0.145 |
<3.5 | 12 (37.5) | 9 (21.96) |
|
≥3.5 | 20 (62.5) | 32 (78.04) |
|
血清白蛋白(g/L) |
|
| 0.046 |
<35 | 5 (15.625) | 15 (36.59) |
|
≥35 | 27 (84.375) | 26 (63.41) |
|
淋巴细胞计数(109/L) |
|
| 0.007 |
<1.1 | 3 (9.375) | 15 (36.59) |
|
≥1.1 | 29 (90.625) | 26 (63.41) |
|